{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T16:19:11Z","timestamp":1782317951767,"version":"3.54.5"},"reference-count":96,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"NIH\/NCI Cancer Center Support Grant","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","geriatriconcology.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Geriatric Oncology"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.jgo.2018.06.009","type":"journal-article","created":{"date-parts":[[2018,7,17]],"date-time":"2018-07-17T13:18:07Z","timestamp":1531833487000},"page":"389-397","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Immunotherapy and targeted therapies in older patients with advanced melanoma; Young International Society of Geriatric Oncology review paper"],"prefix":"10.1016","volume":"10","author":[{"given":"Esther","family":"Bastiaannet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol\u00f2","family":"Battisti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kah Poh","family":"Loh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nienke","family":"de Glas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Soto-Perez-de-Celis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Capucine","family":"Baldini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Kapiteijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Lichtman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.jgo.2018.06.009_bb0005","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s40266-015-0304-7","article-title":"Novel therapies for metastatic melanoma: an update on their use in older patients","volume":"32","author":"Rogiers","year":"2015","journal-title":"Drugs Aging"},{"issue":"2","key":"10.1016\/j.jgo.2018.06.009_bb0010","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/nrclinonc.2013.246","article-title":"Melanoma in 2013: melanoma--the run of success continues","volume":"11","author":"Schadendorf","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"10.1016\/j.jgo.2018.06.009_bb0015","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1200\/JCO.2007.12.7837","article-title":"Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials","volume":"26","author":"Korn","year":"2008","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.jgo.2018.06.009_bb0020","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1111\/j.1468-3083.2007.02475.x","article-title":"Systemic therapy of disseminated malignant melanoma: an evidence-based overview of the state-of-the-art in daily routine","volume":"21","author":"Nashan","year":"2007","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"10.1016\/j.jgo.2018.06.009_bb0025","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1634\/theoncologist.2015-0522","article-title":"Prognosis of mucosal, uveal, acral, nonacral cutaneous, and unknown primary melanoma from the time of first metastasis","volume":"21","author":"Kuk","year":"2016","journal-title":"Oncologist"},{"issue":"8","key":"10.1016\/j.jgo.2018.06.009_bb0030","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11912-016-0534-9","article-title":"Immune checkpoint inhibitors in older adults","volume":"18","author":"Elias","year":"2016","journal-title":"Curr Oncol Rep"},{"issue":"24","key":"10.1016\/j.jgo.2018.06.009_bb0035","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1200\/JCO.2013.54.8347","article-title":"International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer","volume":"32","author":"Wildiers","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jgo.2018.06.009_bb0040","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1586\/14737140.2015.961426","article-title":"Malignant melanoma in elderly patients: biological, surgical and medical issues","volume":"15","author":"Russo","year":"2015","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.jgo.2018.06.009_bb0045","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1742-4933-5-11","article-title":"Immunity, ageing and cancer","volume":"5","author":"Derhovanessian","year":"2008","journal-title":"Immun Age"},{"issue":"9","key":"10.1016\/j.jgo.2018.06.009_bb0050","first-page":"1680","article-title":"T cell replicative senescence in human aging","volume":"19","author":"Chou","year":"2013","journal-title":"Curr Pharm Des"},{"issue":"8","key":"10.1016\/j.jgo.2018.06.009_bb0055","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1634\/theoncologist.2016-0450","article-title":"Impact of age on outcomes with immunotherapy for patients with melanoma","volume":"22","author":"Betof","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.jgo.2018.06.009_bb0060","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ctrv.2016.02.006","article-title":"Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: a systematic review and meta-analysis","volume":"45","author":"Nishijima","year":"2016","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"10.1016\/j.jgo.2018.06.009_bb0065","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S1470-2045(14)70051-8","article-title":"Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study","volume":"15","author":"Larkin","year":"2014","journal-title":"Lancet Oncol"},{"issue":"8\u20139","key":"10.1016\/j.jgo.2018.06.009_bb0070","first-page":"426","article-title":"The immunogenic properties of human melanomas and melanoma-associated antigens recognized by cytotoxic T lymphocytes","volume":"99","author":"Zeuthen","year":"1998","journal-title":"Bratisl Lek Listy"},{"issue":"6","key":"10.1016\/j.jgo.2018.06.009_bb0075","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1097\/01.cco.0000142070.45097.68","article-title":"A review of recent findings involving interleukin-2-based cancer therapy","volume":"16","author":"Eklund","year":"2004","journal-title":"Curr Opin Oncol"},{"issue":"7","key":"10.1016\/j.jgo.2018.06.009_bb0080","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.1999.17.7.2105","article-title":"High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993","volume":"17","author":"Atkins","year":"1999","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.jgo.2018.06.009_bb0085","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1158\/1078-0432.CCR-10-1114","article-title":"Direct effects of type I interferons on cells of the immune system","volume":"17","author":"Hervas-Stubbs","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.jgo.2018.06.009_bb0090","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.1996.14.1.7","article-title":"Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684","volume":"14","author":"Kirkwood","year":"1996","journal-title":"J Clin Oncol"},{"issue":"5796","key":"10.1016\/j.jgo.2018.06.009_bb0095","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1126\/science.1129003","article-title":"Cancer regression in patients after transfer of genetically engineered lymphocytes","volume":"314","author":"Morgan","year":"2006","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.jgo.2018.06.009_bb0100","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1200\/JCO.2005.00.240","article-title":"Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma","volume":"23","author":"Dudley","year":"2005","journal-title":"J Clin Oncol"},{"issue":"32","key":"10.1016\/j.jgo.2018.06.009_bb0105","doi-asserted-by":"crossref","first-page":"5233","DOI":"10.1200\/JCO.2008.16.5449","article-title":"Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens","volume":"26","author":"Dudley","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2018.06.009_bb0110","unstructured":"1alimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. 1-9-2017. Ref Type: Internet Communication."},{"issue":"1","key":"10.1016\/j.jgo.2018.06.009_bb0115","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am J Clin Oncol"},{"issue":"8","key":"10.1016\/j.jgo.2018.06.009_bb0120","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.jgo.2018.06.009_bb0125","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1056\/NEJMc1509660","article-title":"Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.jgo.2018.06.009_bb0130","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1586\/era.12.132","article-title":"Ipilimumab in melanoma","volume":"12","author":"Specenier","year":"2012","journal-title":"Expert Rev Anticancer Ther"},{"issue":"2","key":"10.1016\/j.jgo.2018.06.009_bb0135","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.coi.2006.01.011","article-title":"Principles and use of anti-CTLA4 antibody in human cancer immunotherapy","volume":"18","author":"Peggs","year":"2006","journal-title":"Curr Opin Immunol"},{"issue":"11","key":"10.1016\/j.jgo.2018.06.009_bb0140","doi-asserted-by":"crossref","first-page":"7746","DOI":"10.4049\/jimmunol.175.11.7746","article-title":"Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade","volume":"175","author":"Maker","year":"2005","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.jgo.2018.06.009_bb0145","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1470-2045(09)70334-1","article-title":"Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study","volume":"11","author":"Wolchok","year":"2010","journal-title":"Lancet Oncol"},{"issue":"26","key":"10.1016\/j.jgo.2018.06.009_bb0150","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.jgo.2018.06.009_bb0155","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1200\/JCO.2014.56.6018","article-title":"Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial","volume":"33","author":"Maio","year":"2015","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.jgo.2018.06.009_bb0160","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.jgo.2018.06.009_bb0165","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of Ipilimumab in unresectable or metastatic melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jgo.2018.06.009_bb0170","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.jgo.2018.06.009_bb0175","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","article-title":"Prolonged survival in stage III melanoma with Ipilimumab adjuvant therapy","volume":"375","author":"Eggermont","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgo.2018.06.009_bb0180","doi-asserted-by":"crossref","unstructured":"Chiarion S, V, Pigozzo J, Ascierto PA, Grimaldi AM, Maio M, Di GL, et al. Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme. J Exp Clin Cancer Res 2014 Apr 4;33:30.","DOI":"10.1186\/1756-9966-33-30"},{"key":"10.1016\/j.jgo.2018.06.009_bb0185","doi-asserted-by":"crossref","unstructured":"Friedman CF, Horvat TZ, Minehart J. Efficacy and safety of checkpoint blockade for treatment of advanced melanoma (mel) in patients (pts) age 80 and older (80+). American Society of Clinical Oncology annual meeting. 2016. [Ref type: Abstract].","DOI":"10.1200\/JCO.2016.34.15_suppl.10009"},{"issue":"12","key":"10.1016\/j.jgo.2018.06.009_bb0190","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/nri2873","article-title":"Sterile inflammation: sensing and reacting to damage","volume":"10","author":"Chen","year":"2010","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"10.1016\/j.jgo.2018.06.009_bb0195","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S0952-7915(02)00398-9","article-title":"New regulatory co-receptors: inducible co-stimulator and PD-1","volume":"14","author":"Okazaki","year":"2002","journal-title":"Curr Opin Immunol"},{"issue":"3","key":"10.1016\/j.jgo.2018.06.009_bb0200","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/ni1443","article-title":"The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection","volume":"8","author":"Sharpe","year":"2007","journal-title":"Nat Immunol"},{"issue":"7","key":"10.1016\/j.jgo.2018.06.009_bb0205","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1084\/jem.193.7.839","article-title":"B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells","volume":"193","author":"Tseng","year":"2001","journal-title":"J Exp Med"},{"issue":"3","key":"10.1016\/j.jgo.2018.06.009_bb0210","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/85330","article-title":"PD-L2 is a second ligand for PD-1 and inhibits T cell activation","volume":"2","author":"Latchman","year":"2001","journal-title":"Nat Immunol"},{"issue":"7","key":"10.1016\/j.jgo.2018.06.009_bb0215","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J Exp Med"},{"issue":"12","key":"10.1016\/j.jgo.2018.06.009_bb0220","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/70932","article-title":"B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion","volume":"5","author":"Dong","year":"1999","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.jgo.2018.06.009_bb0225","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/0008-5472.CAN-03-3259","article-title":"PD-L1\/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells","volume":"64","author":"Blank","year":"2004","journal-title":"Cancer Res"},{"issue":"19","key":"10.1016\/j.jgo.2018.06.009_bb0230","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1158\/1078-0432.CCR-14-2607","article-title":"Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors","volume":"21","author":"Patnaik","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.jgo.2018.06.009_bb0235","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma","volume":"369","author":"Hamid","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgo.2018.06.009_bb0240","series-title":"ASCO meeting","article-title":"Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL)","author":"Ribas","year":"2014"},{"issue":"9948","key":"10.1016\/j.jgo.2018.06.009_bb0245","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","article-title":"Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial","volume":"384","author":"Robert","year":"2014","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.jgo.2018.06.009_bb0250","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial","volume":"16","author":"Ribas","year":"2015","journal-title":"Lancet Oncol"},{"issue":"10105","key":"10.1016\/j.jgo.2018.06.009_bb0255","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)","volume":"390","author":"Schachter","year":"2017","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.jgo.2018.06.009_bb0260","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1001\/jama.2014.13943","article-title":"Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial","volume":"312","author":"Hodi","year":"2014","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.jgo.2018.06.009_bb0265","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.jgo.2018.06.009_bb0270","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1200\/JCO.2016.71.8023","article-title":"Overall survival in patients with advanced melanoma who received Nivolumab versus Investigator's choice chemotherapy in CheckMate 037: a randomized, controlled, open-label phase III trial","volume":"36","author":"Larkin","year":"2018","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.jgo.2018.06.009_bb0275","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000007325","article-title":"Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: a systematic review and meta-analysis of randomized controlled trials","volume":"96","author":"Hao","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"21","key":"10.1016\/j.jgo.2018.06.009_bb0280","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.jgo.2018.06.009_bb0285","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined Nivolumab and Ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"issue":"34","key":"10.1016\/j.jgo.2018.06.009_bb0290","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1200\/JCO.2016.72.1167","article-title":"Pooled analysis safety profile of Nivolumab and Ipilimumab combination therapy in patients with advanced melanoma","volume":"35","author":"Sznol","year":"2017","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.jgo.2018.06.009_bb0295","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1200\/JCO.2010.32.4327","article-title":"Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma","volume":"29","author":"Long","year":"2011","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.jgo.2018.06.009_bb0300","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jgo.2018.06.009_bb0305","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(14)70012-9","article-title":"Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): Extended follow-up of a phase 3, randomised, open-label study","volume":"15","author":"McArthur","year":"2014","journal-title":"Lancet Oncol"},{"issue":"9839","key":"10.1016\/j.jgo.2018.06.009_bb0310","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.jgo.2018.06.009_bb0315","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N Engl J Med"},{"issue":"9992","key":"10.1016\/j.jgo.2018.06.009_bb0320","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial","volume":"386","author":"Long","year":"2015","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.jgo.2018.06.009_bb0325","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1093\/annonc\/mdx176","article-title":"Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E\/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study","volume":"28","author":"Long","year":"2017","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.jgo.2018.06.009_bb0330","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgo.2018.06.009_bb0335","series-title":"European Society for Medical Oncology meeting","article-title":"Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib + trametinib in patients with unresectable or metastatic BRAF V600E\/K-mutant cutaneous melanoma (abstract LBA40)","author":"Robert","year":"2016"},{"issue":"12","key":"10.1016\/j.jgo.2018.06.009_bb0340","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/S1470-2045(16)30578-2","article-title":"Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials","volume":"17","author":"Long","year":"2016","journal-title":"Lancet Oncol"},{"issue":"20","key":"10.1016\/j.jgo.2018.06.009_bb0345","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N Engl J Med"},{"issue":"suppl abstract 9006","key":"10.1016\/j.jgo.2018.06.009_bb0350","article-title":"Update of progression-free survival (PFS) and correlative biomarker analysis from coBRIM: Phase III study of cobimetinib (cobi) plus vemurafenib (vem) in advanced BRAF-mutated melanoma","volume":"33","author":"Larkin","year":"2015","journal-title":"J Clin Oncol"},{"issue":"suppl abstract 9007","key":"10.1016\/j.jgo.2018.06.009_bb0355","article-title":"A phase Ib\/II study of BRAF inhibitor (BRAFi) encorafenib (ENCO) plus MEK inhibitor (MEKi) binimetinib (BINI) in cutaneous melanoma patients naive to BRAFi treatment","volume":"33","author":"Sullivan","year":"2015","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.jgo.2018.06.009_bb0360","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1634\/theoncologist.2012-0333","article-title":"Analysis of dermatologic events in vemurafenib-treated patients with melanoma","volume":"18","author":"Lacouture","year":"2013","journal-title":"Oncologist"},{"issue":"8","key":"10.1016\/j.jgo.2018.06.009_bb0365","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1200\/JCO.2013.49.5572","article-title":"Incidence of new primary melanomas after diagnosis of stage III and IV melanoma","volume":"32","author":"Zimmer","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2018.06.009_bb0370","unstructured":"National Comprehensive Cancer Network.Melanoma (Version 1.2018). 2017. Ref Type: Internet Communication."},{"issue":"7","key":"10.1016\/j.jgo.2018.06.009_bb0375","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1200\/JCO.2016.69.3143","article-title":"Performance of four frailty classifications in older patients with cancer: prospective elderly cancer patients cohort study","volume":"35","author":"Ferrat","year":"2017","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.jgo.2018.06.009_bb0380","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nrclinonc.2017.72","article-title":"Combining drugs and extending treatment - a PFS end point is not sufficient","volume":"14","author":"Gyawali","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"10.1016\/j.jgo.2018.06.009_bb0385","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1470-2045(16)30126-7","article-title":"Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial","volume":"17","author":"Weber","year":"2016","journal-title":"Lancet Oncol"},{"issue":"Suppl. 3","key":"10.1016\/j.jgo.2018.06.009_bb0390","first-page":"30","article-title":"Identification and management of toxicities from immune checkpoint-blocking drugs","volume":"28","author":"Teply","year":"2014","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.jgo.2018.06.009_bb0395","article-title":"Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy","author":"Brahmer","year":"2018"},{"issue":"6","key":"10.1016\/j.jgo.2018.06.009_bb0400","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1634\/theoncologist.2012-0483","article-title":"Ipilimumab and its toxicities: a multidisciplinary approach","volume":"18","author":"Fecher","year":"2013","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.jgo.2018.06.009_bb0405","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1001\/jamaoncol.2017.2391","article-title":"Measuring toxic effects and time to treatment failure for Nivolumab plus Ipilimumab in melanoma","volume":"4","author":"Shoushtari","year":"2018","journal-title":"JAMA Oncol"},{"issue":"25","key":"10.1016\/j.jgo.2018.06.009_bb0410","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1200\/JCO.2011.34.7625","article-title":"Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study","volume":"29","author":"Hurria","year":"2011","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.jgo.2018.06.009_bb0415","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1002\/cncr.26646","article-title":"Predicting the risk of chemotherapy toxicity in older patients: the chemotherapy risk assessment scale for high-age patients (CRASH) score","volume":"118","author":"Extermann","year":"2012","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.jgo.2018.06.009_bb0420","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1080\/13543784.2017.1369043","article-title":"Considerations for clinical trial design in older adults with cancer","volume":"26","author":"Soto-Perez-De-Celis","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.jgo.2018.06.009_bb0425","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.critrevonc.2017.06.001","article-title":"Biomarkers of response to PD-1\/PD-L1 inhibition","volume":"116","author":"Maleki","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"issue":"5","key":"10.1016\/j.jgo.2018.06.009_bb0430","first-page":"449","article-title":"Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma","volume":"63","author":"Kelderman","year":"2014","journal-title":"Cancer Immunol Immunother"},{"issue":"14","key":"10.1016\/j.jgo.2018.06.009_bb0435","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.93433","article-title":"Partially exhausted tumor-infiltrating lymphocytes predict response to combination immunotherapy","volume":"2","author":"Loo","year":"2017","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.jgo.2018.06.009_bb0440","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s40425-017-0272-z","article-title":"Whole-blood RNA transcript-based models can predict clinical response in two large independent clinical studies of patients with advanced melanoma treated with the checkpoint inhibitor, tremelimumab","volume":"5","author":"Friedlander","year":"2017","journal-title":"J Immunother Cancer"},{"issue":"8","key":"10.1016\/j.jgo.2018.06.009_bb0445","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-014880","article-title":"Multiple treatment comparison of seven new drugs for patients with advanced malignant melanoma: a systematic review and health economic decision model in a Norwegian setting","volume":"7","author":"Pike","year":"2017","journal-title":"BMJ Open"},{"issue":"9","key":"10.1016\/j.jgo.2018.06.009_bb0450","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s40273-017-0517-1","article-title":"Cost-effectiveness of drug treatments for advanced melanoma: a systematic literature review","volume":"35","author":"Rubio-Rodriguez","year":"2017","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jgo.2018.06.009_bb0455","series-title":"Supportive care for patients undergoing immunotherapy. Support Care Cancer","author":"Rapoport","year":"2017"},{"issue":"suppl_4","key":"10.1016\/j.jgo.2018.06.009_bb0460","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"issue":"18","key":"10.1016\/j.jgo.2018.06.009_bb0465","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1200\/JCO.2014.60.0379","article-title":"Toxicities of immunotherapy for the practitioner","volume":"33","author":"Weber","year":"2015","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jgo.2018.06.009_bb0470","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.cllc.2017.03.005","article-title":"Assessment of the external validity of the National Comprehensive Cancer Network and European Society for Medical Oncology guidelines for non-small-cell lung cancer in a population of patients aged 80 years and older","volume":"18","author":"Battisti","year":"2017","journal-title":"Clin Lung Cancer"},{"issue":"3","key":"10.1016\/j.jgo.2018.06.009_bb0475","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ctrv.2014.12.014","article-title":"Assessing treatment effects in older breast cancer patients: systematic review of observational research methods","volume":"41","author":"de Glas","year":"2015","journal-title":"Cancer Treat Rev"},{"issue":"7","key":"10.1016\/j.jgo.2018.06.009_bb0480","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1080\/14737140.2017.1341315","article-title":"Checkpoint inhibitors in advanced melanoma: effect on the field of immunotherapy","volume":"17","author":"O'Reilly","year":"2017","journal-title":"Expert Rev Anticancer Ther"}],"container-title":["Journal of Geriatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406818301966?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406818301966?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T09:50:42Z","timestamp":1761817842000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879406818301966"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":96,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S1879406818301966"],"URL":"https:\/\/doi.org\/10.1016\/j.jgo.2018.06.009","relation":{},"ISSN":["1879-4068"],"issn-type":[{"value":"1879-4068","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy and targeted therapies in older patients with advanced melanoma; Young International Society of Geriatric Oncology review paper","name":"articletitle","label":"Article Title"},{"value":"Journal of Geriatric Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgo.2018.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}